Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Masaru Ubasawa is active.

Publication


Featured researches published by Masaru Ubasawa.


Antimicrobial Agents and Chemotherapy | 1990

Anti-human immunodeficiency virus type 1 activities and pharmacokinetics of novel 6-substituted acyclouridine derivatives.

Masanori Baba; E. De Clercq; S Iida; H Tanaka; Issei Nitta; Masaru Ubasawa; H Takashima; K Sekiya; K Umezu; Hiroshi Nakashima

The novel 6-substituted acyclouridine derivatives 1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine (HEPT), 1-[(2-hydroxyethoxy)methyl]-6-(3-methylphenylthio)thymine (HEPT-M), 6-cyclohexylthio-1-[(2-hydroxyethoxy) methyl]thymine (HEPT-H), and 1-[(2-hydroxyethoxy)methyl]-6-phenylthio-2- thiothymine (HEPT-S) have proved to be potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) replication in a variety of cell systems, including peripheral blood lymphocytes. They are not inhibitory to the replication of HIV-2. HEPT-S emerged as the most active congener, with a 50% inhibitory concentration of 1.6 microM for HIV-1 (human T-cell lymphotropic virus type IIIB) in MT-4 cells. We also examined the pharmacokinetics of the compounds following oral administration to rats. The pharmacokinetic profile varied considerably from one compound to another. The highest concentration in plasma (7.4 micrograms/ml, or 22.8 microM) was achieved by HEPT-S within 30 min after administration of an oral dose of 20 mg/kg of body weight. HEPT-S can be considered a promising candidate for the treatment of HIV-1 infections.


European Journal of Medicinal Chemistry | 1996

Molecular simulation of 5,6-substituted 1-[(2-hydroxyethoxy)methyl]uracils with anti-HIV-1 activity

E. De Clercq; H Takashima; Masaru Ubasawa; K Sekiya; Masanori Baba; H Walther

Summary The dioxypyrimidine ring of 5,6-substituted 1-[(2-hydroxyethoxy)methyl]uracils is an extended ‘partial π system’ with ring distortion. PM3-MM+ geometry optimization suggested a lipophilic ‘butterfly-like’ orientation which was also found in other non-nucleoside inhibitors that interact with the HIV-1 reverse transcriptase. Multivariate QSAR has shown that discrimination between the antiviral response and undesired cytotoxicity is possible. Related to the C-6 thiophenyl ring substituents and to modifications at the C-5 position, the antiviral response depends on hydrogen-bonding forces, steric parameters, and electronic properties. The cytotoxicity depends on the lipophilicity and steric parameters.


Nucleosides, Nucleotides & Nucleic Acids | 1998

Some Aspects on Acyclonucleoside Synthesis

Masaru Ubasawa; Hideaki Takashima; Kouichi Sdciya

Abstract An acyclonucleoside synthesis was investigated on the regioselective introduction of an acyclochain. We found that iodotrimethylsilane catalyzed the reaction of acyclochain introduction as well as its migration from S2 to N1 of 2-thiothymine and from N7 to N9 position of guanine. By taking the findings into account, several acyclo-nucleosides were synthesized in a simple one-pot procedure.


Proceedings of the National Academy of Sciences of the United States of America | 1991

Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase.

Masanori Baba; E. De Clercq; H Tanaka; Masaru Ubasawa; H Takashima; K Sekiya; Issei Nitta; K Umezu; Hiroshi Nakashima; Shuichi Mori


Antimicrobial Agents and Chemotherapy | 1994

Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro.

Masanori Baba; S Shigeta; Satoshi Yuasa; H Takashima; K Sekiya; Masaru Ubasawa; H Tanaka; Tadashi Miyasaka; R. T. Walker; E. De Clercq


Archive | 1994

Phosphonate-nucleotide ester derivatives

Hideaki Takashima; Naoko Inoue; Masaru Ubasawa; Kouichi Sekiya; Shingo Yabuuchi


Journal of Medicinal Chemistry | 1991

Specific anti-HIV-1 "acyclonucleosides" which cannot be phosphorylated: synthesis of some deoxy analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.

H Tanaka; Masanori Baba; S. Saito; Tadashi Miyasaka; H Takashima; K Sekiya; Masaru Ubasawa; Issei Nitta; R. T. Walker; Hiroshi Nakashima; E. De Clercq


Archive | 1997

Phosphonate nucleotide compounds

Masaru Ubasawa; Kouichi Sekiya; Hideaki Takashima; Naoko Ueda; Satoshi Yuasa; Naohiro Kamiya


Molecular Pharmacology | 1991

Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives.

Masanori Baba; E. De Clercq; H Tanaka; Masaru Ubasawa; H Takashima; K Sekiya; Issei Nitta; K Umezu; R. T. Walker; Shuichi Mori; Masahiko Ito; S Shigeta; Tadashi Miyasaka


Molecular Pharmacology | 1993

Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442.

S Yuasa; Y Sadakata; H Takashima; K Sekiya; N Inouye; Masaru Ubasawa; Masanori Baba

Collaboration


Dive into the Masaru Ubasawa's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

H Tanaka

Mitsubishi Chemical Corporation

View shared research outputs
Top Co-Authors

Avatar

Tadashi Miyasaka

Mitsubishi Chemical Corporation

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

E. De Clercq

Rega Institute for Medical Research

View shared research outputs
Top Co-Authors

Avatar

Hideaki Takashima

Mitsubishi Chemical Corporation

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Richard Thomas Walker

Mitsubishi Chemical Corporation

View shared research outputs
Researchain Logo
Decentralizing Knowledge